



ADVITECH ANNOUNCES THAT DERMYLEX™ IS NOW AVAILABLE UNDER THE PSOPAX® BRAND NAME IN FRANCE AND BELGIUM

FOR IMMEDIATE RELEASE

TSX VENTURE EXCHANGE: AVI

QUEBEC CITY, QUEBEC — December 4, 2007 — Advitech Inc. (“Advitech” or the “Corporation”) (TSX Venture Exchange: AVI) today announced that Iprad Santé S.A. has started the commercialization in France and Belgium of Dermylex™ under the Psopax® brand.

Psopax® will be officially presented during the “Journées Dermatologiques” in Paris, an annual conference on dermatology. This conference is an annual meeting point for French and European dermatologists which will be held from December 4th to 8th.

Iprad Santé employs more than 105 medical representatives and 32 marketing representatives on the French and Belgium markets. Psopax® is now available in all French and Belgium drugstores.

About Dermylex™ (Psopax® in France and Belgium)

Dermylex™, developed by Advitech, is an oral natural health product formulated to improve mild-to-moderate psoriasis symptoms. Two clinical trials, including a 112-day, multi-center, double-blind, placebo-controlled trial with 84 patients, clinically proved the efficacy and safety of Dermylex™ for that type of psoriasis. For more information on Dermylex™ please consult the web site at www.dermylex.com.

Dermylex™ is also available in Canada in drugstores and in the US in health professionals' clinics under the BioDerm brand.

About Advitech Inc. www.advitech.com

Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Recently, Advitech launched Dermylex™ for the treatment of mild-to-moderate psoriasis.

About The Iprad Group: www.groupeiprad.com

Iprad Group consists of two different business units: Iprad Laboratory develops pharmaceutical products and Iprad Santé commercializes cosmeceutical products and food supplements for the Iprad Group. Iprad Santé S.A. employs on the French and Belgian territories 105 medical visitors and 32 commercial representatives. Their main products target the dermatological, gynaecological and gastroenterology markets and they have generated, in 2006, sales of more than 40 millions Euros. Iprad Group has experienced a strong growth over the past ten years and it intends to maintain this growth by adding up products specific to dermatology.

This press release contains forward-looking statements which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Advitech Inc.

Renaud Beaudesne, MBA
President and Chief Executive Officer
418-686-7498, ext. 228
info@advitech.com
www.advitech.com

Serge Comeau
Investor's relations
514-862-4160
s.comeau@advitech.com